Latest News

Researchers in the UK have developed a new treatment approach for aniridia-related keratopathy (ARK), a rare genetic ocular disease, namely, a collagen scaffold that delivers limbal epithelial stem cells and stromal stem cells to the area affected by ARK. The treatment resulted in improved ocular surface scores and visual acuities.

AI model beats human graders at spotting glaucoma risk in UK population retinal photos, boosting accuracy and strengthening the case for scalable AI vision screening.

A maternal high-fat diet can negatively affect the retinal structure in mice.

In this Q&A from EDES 2026 in Milan, Piotr A. Woźniak, MD, PhD, discusses his real-world evidence study on a dry eye lubricating drop, including its effects on tear film stability.

An investigational treatment for vision loss associated with Bardet-Biedl syndrome is being tested in the first three patients treated.

Private practice fellowships sharpen cataract and refractive skills with high volume, new tech, and hands-on practice management mentorship.

Waste, cost and carbon are converging to reshape how cataract centres choose instruments.

Home OCT now gives us the next dimension: time.

In this Q&A, Vance Thompson, MD, clears up myths about dry eye and LASIK wearing off, and explains how better screening and technology are making the procedure more precise for younger patients.

The phase 2 Early Vitrectomy and Intravitreal Antibiotics for Post-Operative Exogenous Endophthalmitis study showed that performing early vitrectomy for acute endophthalmitis can offer better and faster visual outcomes than the current treatment of prescribing antibiotics first.

Susvimo works in conjunction with the company’s port delivery platform, Contivue, which was specifically engineered for use with Susvimo.

Why AI-driven functional imaging could change how clinicians assess and treat retinal disease

PRIMA, the first brain-computer interface approved for form vision restoration (reading letters, numbers, words) in patients with geographic atrophy (GA) secondary to age-related macular degeneration, is commercially available in Europe.